1. Global Portfolio of Antimalarial Medicines
Translational
Product development
Access
Advanced Non-clinical
Human volunteers
Patient exploratory
Patient confirmatory
Regulatory review
Approved/ERP
SAR121
Sanofi
P218
Janssen
Artemisone
UHKST
Artefenomel/
Ferroquine
Sanofi
Dihydroartemisinin- piperaquine
dispersible
Alfasigma
Arterolane-
piperaquine
Sun Pharma ▲
Artemether-
lumefantrine
Various Manufactures
Artesunate-
amodiaquine
Various Manufacturers 1 6 3
AN13762
SJ733
Kentucky/Eisai
AQ13
Immtech
KAF156/
Lumefantrine
Novartis
Artemether-
lumefantrine
Dispersible
Various Manufacturers
Artesunate-
mefloquine
Cipla
Co-trimoxazole
ITM Antwerp 2
ACS Inhibitor
GSK Wellcome Trust
ACT
Actelion
Sevuparin
Dilaforette
Cipargamin
Novartis
Artemisinin-
naphthoquine
Kunming Pharma Co ▲
Artesunate
for Injection
Guilin
Sulfadoxine-
pyrimethamine+
amodiaquine
Guilin 3 7
NPC1161B
Mississippi
CDRI 9778
Ipca
MMV048
DSM265
Takeda
Artemether sub-lingual spray
MRC/Suda
Dihydroartemisinin- piperaquine
Various manufacturers
Rectal artesunate
Cipla 4
MK4815
Merck
N-tert butyl Isoquine
LSTM/Liverpool/GSK
Rosiglitazone adjunct therapy Manhica, Toronto, Barcelona
Fosmidomycin Piperaquine
DMG Deutsche Malaria GmbH
Sulfadoxine-
pyrimethamine+
Amodiaquine dispersible S Kant
Pyronaridine-
Artesunate Shin Poong
Rectal artesunate
Strides Shasun 5
Novel DHODH
University of Leeds
M5717
Merck KGaA
Immatinib
HuLow, Purdue, Turin, Sassari and Hue
Methylene Blue/ amodiaquine
Heidelberg
Artesunate-
amodiaquine
Sanofi
Pyronaridine-
artesunate granules
Shin Poong
Tafenoquine
GSK/MMV
Artemisinin-piperaquine
Artepharm 8 5
MMV253
Zydus Cadila
SAR97276
Sanofi
Tafenoquine
60P/US Army 9
SC83288
Heidelberg University
DM1157
DesignMedix
Footnotes: Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ. │ Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing. │ WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers. │ Paediatric formulation.
Isoxazolines
Calibr TropIQ
(Status of tafenoquine & Strides Shasun rectal artesunate updated September 2018)

2. Footnotes: Global Portfolio
Target Product Profiles and Target Candidate Profiles
MMV has defined Target Product Profiles and Target Candidate Profiles for medicines to support the eradication campaign.
Burrows JN et al., New developments in anti‑malarial target candidate and product profiles et al. Malar J (2017) 16:26 updates the previous profiles in Burrows J et al.; Malaria Journal :187
Target Product Profiles
indicated by bars at the bottom of each compound box
Target Candidate Profiles
activities for each individual molecule, indicated by symbols added to each compound in the translational portfolio
Burrows Burrows
et al., 2013 et al., 2017
Asexual blood stages (TCP-1,2) TCP-1
Relapse prevention (TCP-3a) TCP-3
Transmission reduction (TCP-3b) TCP-5,6
Chemoprotection (TCP- 4) TCP-4
3-day cure, artemisinin-based combination therapies
Combinations aiming at a new single-exposure radical cure (SERC) TPP-1
Severe malaria treatment and pre-referral intervention
Intermittent/seasonal malaria chemoprevention
Products targeting prevention of relapse for P. vivax
Single-exposure chemoprotection (SEC) TPP-2
Footnote for Generic names on Global Portfolio
1.  First approval: Novartis (Brand name: Coartem®). Generics by Ajanta, Cipla, Ipca, Strides Shasun, Macleods, Mylan  
First approval: Novartis (Brand name: Coartem® Dispersible). Generics by Ajanta; Cipla; Strides Shasun; Ipca
Brand name: Artesun®
First approval: Alfasigma (Brand name: Eurartesim®). Generic by Guilin
Brand name: Pyramax® tablets and granules
First approval fixed-dose combination: Sanofi/DNDi (Brand name: ASAQ Winthrop). Generics by Ajanta, Cipla, Guilin, Ipca, Strides Shasun
Brand name: SPAQ-COTM
Brand names: Krintafel/Kozenis (Trademarks owned or licensed by GSK)
Brand names: ARAKODATM/KODATEF
Additional Symbols on Global Portfolio
Brought into portfolio after approval; collaborations with DNDi
No progress report in the last two years
Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.
Paediatric formulation
WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.
Approved in several countries but not approved by WHO pre- qualification nor regulatory bodies who are ICH members or observers ▲